Immune checkpoint inhibitors targeting the programmed cell death 1 (PD-1) receptor and its ligand, programmed death ligand 1 (PD-L1), have emerged as a therapeutic approach for patients with non-small cell lung carcinoma (NSCLC). PD-L1 expression, assessed by immunohistochemistry (IHC), is used to select patients for PD-1/PD-L1 inhibitor therapy. Most studies have been performed with histology specimens, with limited data available on the performance in cytology specimens. This study evaluated PD-L1 in cytology specimens and compared the results with those from paired core-needle biopsy for concordance. METHODS: Forty-one NSCLC fine-needle aspiration cases that had paired coreneedle biopsy specimens with PD-L1 IHC were selected. A Papanicolaou-stained direct smear and a cell block section from each case were stained with a Dako PD-L1 pharmDx antibody (clone 22C3). Only slides with 100 or more tumor cells (37 smears and 38 cell blocks) were evaluated. Tumor proportion scores (TPS) were assessed on the basis of the partial/ complete membranous staining of tumor cells and were correlated with those of paired core-needle biopsy. RESULTS: All 9 smears that were negative for PD-L1 staining showed 100% concordance with the paired core-needle biopsy, whereas 28 smears with PD-L1 expression showed a similar TPS, except for 1 smear that was discordant. In contrast, 10 negative paired core-needle biopsy cases corresponded to 9 concordant negative cell blocks, whereas 1 cell block had a TPS of 1% to 5%. The remaining 28 cell blocks demonstrated PD-L1 expression, with 22 cases showing a TPS similar to that of the paired core-needle biopsy, whereas 6 cell blocks were discordant, likely because of intratumoral heterogeneity. CONCLU-
INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality, with non-small cell lung carcinoma (NSCLC) accounting for more than 85% of cases. 1, 2 Most patients with NSCLC are diagnosed at an advanced stage, and 5-year survival rates are extremely poor. In the absence of targetable activating mutations in epidermal growth factor receptor (EGFR) or translocations/gene rearrangements in anaplastic lymphoma kinase (ALK) and ROS Proto-Oncogene 1 (ROS1) that preclude tyrosine kinase inhibitor therapy, platinum-based chemotherapy remains the first-line treatment for advanced-stage NSCLC. 3, 4 With chemotherapy response rates ranging between 15%
and 30%, the overall survival and progression-free survival of patients with advanced-stage NSCLC remain low. 4 Recently, a new therapeutic approach has emerged with immune checkpoint inhibition. Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1)-nivolumab, pembrolizumab, and atezolizumab-have shown promising therapeutic responses in patients with NSCLC. [5] [6] [7] [8] [9] [10] [11] [12] [13] The therapeutic efficacy attributed to these drugs is known to occur via inhibition of the PD-1 protein pathway: the interaction between programmed death ligand 1 (PD-L1), an apoptosis-associated molecule, and the PD-1 receptor is interrupted. This interruption carries the potential to result in an antitumor cellular immune response. Currently, the therapeutic efficacy of the immune checkpoint inhibitors nivolumab, pembrolizumab, and atezolizumab is related to the expression of PD-L1 protein in NSCLC tumor cells. The 2017 National Comprehensive Cancer Network guidelines recommend testing for PD-L1 expression on tumor cells in patients with advanced NSCLC.
14 PD-L1 expression is evaluated by immunohistochemistry (IHC) staining with specific PD-L1 antibody clones. Three commercial PD-L1 diagnostic tests for pembrolizumab (Dako 22C3 pharmDx), nivolumab (Dako 28-8 pharmDx), and atezolizumab (Ventana SP142) are now approved by the US Food and Drug Administration (FDA) for use in NSCLC. Pembrolizumab was approved by the FDA as a companion diagnostic test (using 22C3) for first-line therapy in patients with advanced NSCLC without EGFR and ALK aberrations and with greater than 50% expression of PD-L1 in tumor cells and as secondline therapy (when PD-L1 expression is found in 1% of tumor cells) in patients without EGFR and ALK aberrations with disease progression on platinum-based chemotherapy. 15 Nivolumab was approved as a complementary diagnostic test (using by the FDA for second-line chemotherapy in patients with previously treated advanced or metastatic NSCLC. 15 Finally, atezolizumab was FDAapproved as a complementary diagnostic tool (using SP142) for use in patients with metastatic NSCLC who have progressed on frontline chemotherapy. 15 Despite the approval of the commercial PD-L1 IHC assays and the relative ease of performing an IHC diagnostic test, there are multiple issues involving the use of PD-L1 IHC as a predictive biomarker. These include preanalytic issues, various antibody clones with different platforms, varying IHC cutoffs, the staining of tumor cells versus immune cells, intratumoral heterogeneity, variability between primary and metastatic tumors, and the subjective nature of the IHC evaluation. 16 The heterogeneous expression of PD-L1 within NSCLC can influence PD-L1 therapeutic regimens. 17 PD-L1 expression is evaluated by a tumor proportion score (TPS), which is the percentage of viable neoplastic cells with at least partial membrane staining with respect to all of the viable neoplastic cells within the examined slide. 15 Studies evaluating PD-L1 expression on IHC stains have predominantly been established with histology specimens (formalin-fixed, paraffin-embedded [FFPE] tissue sections). This presents a problem for a large fraction of patients with advanced-stage NSCLC who are not surgical candidates and are frequently diagnosed via cytology materials. There are limited data available on the suitability and performance of PD-L1 testing in cytology specimens, with very few published studies related to PD-L1 concordance between cytology and histology specimens. [18] [19] [20] These recent studies focused primarily on FFPE cytology cell blocks, and the feasibility of evaluating PD-L1 expression and performance with cytology smears has not been investigated. In this study, we evaluated PD-L1 testing on cytology specimens, including direct smears and/or cell block sections (FFPE), by comparing our results with PD-L1 testing on histology specimens from the same patient.
MATERIALS AND METHODS

Case Selection
Following institutional review board approval, a retrospective review of the pathology database at The University of Texas MD Anderson Cancer Center (Houston, Texas) between January 1, 2014, and December 30, 2016 , and between October 2017 and November 2017 was performed to identify NSCLC surgical core-needle biopsies that had PD-L1 IHC reported and had a corresponding fine-needle aspiration (FNA) sample containing malignant cells. The corresponding FNA samples were reviewed to identify cases with adequate material for the study: 1) an FFPE cell block and a Papanicolaou-stained direct smear were available for PD-L1 immunostaining, and 2) each contained at least 100 tumor cells for the evaluation of PD-L1 expression. From the cases that met the aforementioned criteria, we selected 41 cases for this study. The cases included endobronchial ultrasound-guided FNA (n 5 13), ultrasound-guided FNA (n 5 3), and computed tomography-guided FNA (n 5 25) from a variety of sites, including the lung (n 5 16), lymph node (n 5 12), chest wall (n 5 4), liver (n 5 3), pleura (n 5 2), bone (n 5 2), kidney (n 5 1), and adrenal gland (n 5 1). The FNA samples were either concurrently acquired (n 5 32) with the surgical biopsy from the same site or acquired separately (n 5 9) from a different site than the surgical specimen. The diagnoses included adenocarcinoma (n 5 26), squamous cell carcinoma (n 5 10), and non-small cell carcinoma not otherwise specified (n 5 5). Diagnoses were made according to the 2015 World Health Organization classification of lung tumors.
21,22
Cytology Sample Processing
All cytology samples were collected via image-guided FNA performed at our institution; 2 to 3 passes were made with 20-to 25-gauge needles. Expelled tissue from these needle aspirates was processed as direct smears (Diff-Quik-and/ or Papanicolaou-stained), 23 whereas residual tissue in the needle was rinsed into 10 mL of Roswell Park Memorial Institute 1640 medium and centrifuged at 1500 rpm for 10 minutes. The centrifugate was then mixed in equal amounts of 95% ethanol and 10% formalin, and this was followed by centrifugation at 1500 rpm for another 10 minutes according to standardized procedures within our laboratory. 24 The cell pellet that formed was wrapped in filter paper, placed into a tissue cassette, and further fixed in formalin for tissue processing. After paraffin embedding, tissue sections were cut as 4-lm-thick sections onto slides. The morphologic evaluation was performed by hematoxylin and eosin staining of a cell block section. Unstained sections from the cell blocks and Papanicolaou-stained direct smears were used for immunoperoxidase staining. Coverslips were removed from the Papanicolaou-stained smears with xylene before immunostaining.
PD-L1 Immunoperoxidase Staining and Evaluation
PD-L1 immunostaining was performed with FDAapproved Dako PD-L1 pharmDx (clone 22C3; Dako/Agilent Technologies, Carpinteria, California) on the Dako Autostainer Link 48 autostainer (Dako/Agilent Technologies), and antigen retrieval was performed with PT Link with Target Retrieval Solution (low pH; Dako/Agilent Technologies) as specified by the manufacturer without any modification to adjust for differences in fixation between cytology and histology samples. The specific PD-L1 antibody (clone 22C3) used to evaluate the surgical specimens was used to stain the corresponding cytology Papanicolaoustained direct smears and cell block sections. PD-L1 controls were run concurrently; they included the Dakoprovided positive and negative cell line control as well as an in-house tonsil control that served as a positive tissue control (squamous epithelium in crypts). PD-L1 expression in cytology samples was evaluated independently by 2 cytopathologists. The total number of tumor cells was scored as <100, 100 to 300, or >300. PD-L1 expression was evaluated with the TPS, which was defined as the percentage of viable tumor cells with partial/complete membranous staining with respect to all viable tumor cells within a slide. 15 Cytoplasmic staining without any membranous staining was not included, and staining in other background cells, such as normal/nonneoplastic cells, inflammatory cells, and necrotic cells, was also excluded from evaluation. Only tumor cells that demonstrated an unequivocally malignant cytomorphology and/or had a confirmatory immunostain (eg, thyroid transcription factor 1 and/or p40) on a corresponding cell block section to aid in identification were included in the assessment. The staining intensity score (SIS) was defined as strong when staining was clearly visible with a 43 microscope objective lens, moderate when a 103 or 203 objective lens was required for staining to be clearly seen, and weak when staining was visible only with a 403 microscope objective. TPS and SIS were evaluated for each PD-L1-stained slide (cell block, Papanicolaou-stained smear, and histology section). The scoring of the cytology slides was performed with the scorer blinded to the scoring of the histology slides. Each interpretation was evaluated for interobserver agreement, and TPS that were within a 10% difference were averaged; any case that had >10% discordance was reviewed by the 2 cytopathologists together so that they could arrive at a consensus opinion.
RESULTS
Our study included cytologic and histologic materials from 41 patients. The patient demographics and clinicopathologic characteristics are summarized in Table 2) . Four of the total 41 smears evaluated had to be rejected because there were fewer than 100 tumor cells for evaluation after processing for PD-L1 immunostaining. For 9 of the 37 smears evaluated (24.3%), 0% of tumor cells had membranous staining; 10 cases (27%) had membranous staining in <50% of tumor cells; and for 18 cases (48.7%), 50% of tumor cells had membranous staining (high PD-L1 expression; Fig. 1 ). The staining intensity in the 28 smears with membranous staining showed 12 cases (42.9%) with strong expression, 14 cases (50%) with moderate expression, and 2 cases (7.1%) with weak expression (Table 2) .
In contrast, the 41 matched histology specimens showed 11 cases (26.8%) with membranous staining in 0% of tumor cells, 12 cases (29.3%) with membranous staining in <50% of tumor cells, and 18 cases (43.9%) with 50% tumor cells with membranous staining in (high PD-L1 expression). The staining intensity scores for the 29 histology specimens available for review showed 12 cases (41.4%) with strong expression, 15 cases (51.7%) with moderate expression, and 2 cases (6.9%) with weak expression (Table 2) .
PD-L1 staining in cytology smears showed high concordance with the matched histology specimens. All smears that were scored as negative (0% tumor cells with membranous staining) were 100% concordant with the histologic TPS. Furthermore, the 28 smears with PD-L1 membranous staining in tumor cells mostly showed TPS and SIS values that were identical (n 5 24 [85.7% of the cases]) or comparable (n 5 3 [10.7% of the cases]) to those for the matched histologic cases, whereas 1 case (case 28) was discordant with the histology sample (with TPS values of 80% and 50%, respectively; Table 2 ). The differences in the TPS between the cytology smears and the histologic cases in the 3 cases that were comparable (within 10% of each other) and the 1 case that was discordant did not, however, alter the clinical significance for therapy (<50% vs 50%). Interestingly, the 1 smear that showed discordance with the histologic TPS demonstrated a TPS identical to that of the matched cell block ( Table 2 ). The main issues with the interpretation of the cytology smears were ensuring that an adequate number of tumor cells were present (at least 100 tumor cells) and avoiding an overestimation of PD-L1 expression due to nonspecific cytoplasmic staining, high amounts of staining in nontumor cells (eg, macrophages and inflammatory cells), and background staining of mucus and cellular debris as well as an overestimation of staining intensity due to the inherent 3-dimensionality of the tumor cell clusters (Fig. 2) .
In contrast, PD-L1 staining in cytology cell blocks showed some variability in concordance with the matched histology samples. All 9 cell blocks that were scored as negative (0% tumor cells with membranous staining) showed 100% concordance with the histologic TPS. A single case (case 34) showed 1% to 5% membranous staining of tumor cells in the cell block, whereas the corresponding histology sample from the same patient showed no PD-L1 expression in the tumor cells; this was similar to what was seen in the concurrent direct smear (Fig. 3) . Of the remaining 28 cases that showed membranous staining of PD-L1 on the cell block sections, 22 showed a TPS identical (n 5 14 [50%]) or comparable (n 5 8 [28.6%]) to the 
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TPS of the matched histologic case, whereas 6 cases (21.4%) showed discordance. Among the 6 cell block cases with discordance, cases 4 ( Fig. 4) , 9, 17, and 26 demonstrated a lower TPS on cell block sections in comparison with the histologic cases, whereas case 8 ( Fig. 5) and case 28 demonstrated a higher TPS on the cell block in comparison with the histologic cases ( These slides were not available for re-review at the time of the study; the PD-L1 scores were extracted from the pathology report.
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concordant with the histologic TPS values. In contrast, the TPS for the smear for case 28, though discordant with the histologic case, was identical to that of the cell block ( Table  2 ). The TPS for the smear in case 9 could not be assessed because of the paucity of tumor cells for evaluation.
Among the cell blocks that demonstrated comparable (within 10% of each other) and discordant TPS values in comparison with the histology sample, the change in the TPS would alter the clinical significance for therapy in 6 cases (0% vs <50% vs 50%). The overall PD-L1 staining intensity scores in the cell blocks were identical to those of the histologic cases in 22 cases (75.9%), with 6 cases showing slight discordance ( Table 2 ). The concordance in TPS values between the cytology and the paired histologic case was independent of the overall cellularity of the cases evaluated.
DISCUSSION
Immunotherapy using checkpoint inhibitors has shown promising results in patients with NSCLC, and this has led to accelerated FDA approval of PD-1/PD-L1 inhibitors for first-line and second-line treatments in these patients. The assessment of PD-L1 expression detected by IHC testing, used as a predictive biomarker assay to select patients for PD-1/PD-L1 inhibitor therapy, makes the role of the pathologist critical in these biomarker assessments.
The commercially available PD-L1 IHC 22C3 pharmDx assay was FDA-approved as a companion diagnostic test in patients with advanced NSCLC for treatment with pembrolizumab. Tumors showing high PD-L1 expression (ie, TPS 50%) qualify the patient for firstline therapy with pembrolizumab, whereas PD-L1 expression (ie, TPS > 1%) is required for second-line treatment. 15 High PD-L1 expression is generally associated with a higher objective response rate and favorable outcomes in patients treated with pembrolizumab. 5 The commercially available PD-L1 IHC 28-8 pharmDx assay is an FDA-approved complementary diagnostic tool for treating patients with advanced-stage NSCLC with nivolumab as a second-line therapy when there is disease progression during or after platinum-based chemotherapy. PD-L1 IHC testing is not required as a selection biomarker to treat patients with nivolumab; however, the assay has been approved as a complementary diagnostic tool for the management of NSCLC with PD-L1 expression of 1% or greater with nivolumab. 15 A third FDA-approved complementary diagnostic tool using the Ventana PD-L1 IHC SP142 assay in combination with the PD-L1 inhibitor atezolizumab is also available for use in patients with metastatic NSCLC who have progressed on frontline chemotherapy. 12, 13, 25 Preliminary harmonization studies comparing the different PD-L1 antibody clones have reported significantly lower expression in tumor cells with SP142. 26, 27 In addition, the SP142 clone requires evaluating PD-L1 expression in tumor-related immune cells, and this can be challenging in a cytology sample because of the inherent difficulty of distinguishing relevant tumor-related immune cells from nontumor immune cells that exist outside the tumor boundaries. For biomarker assessment, IHC is frequently preferred by pathologists because it is rapid, easy to perform, and relatively inexpensive and, with appropriate validation, can be successfully performed on a variety of specimen preparations. These include FFPE histologic tissue blocks, FFPE cytology cell blocks, and non-formalin-fixed cytology preparations (eg, direct smears, cytospins, and liquidbased cytology) with appropriate validation studies. 15 However, the use of PD-L1 IHC as a biomarker has been challenging for pathologists because the different assays require different IHC antibody clones, platforms, scoring systems, and cutoffs. In addition, the interpretation is complicated by the intratumoral heterogeneous expression of PD-L1 and by the fact that PD-L1 is a pathophysiologically inducible factor that can have spatially and temporally variable and dynamic expression. [16] [17] [18] 28 PD-L1 expression has traditionally been evaluated on FFPE histology samples, and the literature on PD-L1 testing in cytology samples is very limited. [18] [19] [20] 29 Our study provides some insights into PD-L1 staining in cytology FNA samples, including both smears and cell blocks, and adds to the limited body of evidence on the feasibility of PD-L1 testing in cytology specimens. Our results show an overall concordance of PD-L1 testing between cytology and histology specimens. The cytology direct smears showed good concordance with the histology samples in terms of TPS as well as SIS. Despite differences in fixation methods (alcohol vs formalin), no significant difference in staining intensity was observed between paired cytology and histology samples. This lends support to the recommendation that any PD-L1 staining, regardless of intensity, should be reported. However, it is important to emphasize that one needs to exert caution not to overestimate PD-L1 expression because of nonspecific cytoplasmic staining, high amounts of background staining, and staining of nontumor cells. Our study focused specifically on Papanicolaou-stained direct smears because we routinely perform immunocytochemistry for other biomarkers on these slides; however, because cytology laboratories use a variety of processing techniques (eg, different fixatives and stains), this underscores the need for a rigorous validation protocol by individual laboratories before the utilization and reporting of any clinical assay, including PD-L1 evaluations on cytologic tissue. 15, 30 The cell block sections, on the other hand, showed some discordance with the corresponding histology samples (n 5 6), with either a higher or lower TPS than the latter. This would have therapeutic significance in terms of making a patient eligible for first-line or second-line PD-L1 inhibitor therapy. Interestingly, 3 of the 6 cases with discordant TPS values were not acquired concurrently, and although spatial and temporal factors may account for the variability seen in these samples, in 2 of these cases, the TPS values of the smears were concordant with those of the histology samples. Prior studies have reported marked variability in PD-L1 staining, even within a single tumor specimen, 31 and the tumoral heterogeneity for PD-L1 expression has raised concerns about the concordance of PD-L1 testing between small biopsies and excisional samples. 17, 28, 29 In addition, approximately 10% of NSCLC biopsies that do not express PD-L1 still respond to PD-L1/PD-1 inhibitor therapy, and this suggests a falsenegative result on the small biopsy specimen due to intratumoral heterogeneity. 15 Because a large fraction of NSCLC patients are not surgical candidates and PD-L1 staining will likely be performed on small biopsies and cytology specimens, this discordance due to intratumoral heterogeneity may not be avoidable. Furthermore, PD-L1 expression is known to be inducible after chemotherapy and/or radiation therapy, and the temporal lag between the treatment-naive tissue biopsy used for PD-L1 evaluation and the initiation of PD-L1 treatment as a second-line (or later) therapy might explain the small number of patients who respond to PD-1/PD-L1 inhibitor therapy despite a negative PD-L1 IHC result. However, none of the cases in our cohort that were acquired separately and showed discordant results between the cytology and histology samples had any evidence of chemo/radiation therapy in the interval between the acquisitions of the 2 samples; therefore, the expression of PD-L1 was likely not affected by therapy. The limitations of our study are its small sample size, the lack of data on responses to PD-1/PD-L1 inhibition therapy, and the lack of data on the comparability of the different PD-L1 antibody clones. Some of the recent studies comparing the various antibody clones have shown high concordance among the 28-8, 22C3, and SP263 antibody clones, with lower concordance with the SP142 clone, which consistently stained fewer cells. 26, 27 Further studies using larger data sets will be needed for the further evaluation of comparisons of the different PD-L1 antibody clones to determine whether they can be used interchangeably in cytology samples.
In conclusion, our study shows the feasibility and validity of performing and interpreting PD-L1 testing in NSCLC with cytology cell blocks as well as direct smears. PD-L1 testing in cytology was mostly concordant with corresponding histology samples from the same patient; there were rare exceptions that were likely due to intratumoral heterogeneity. Our study demonstrates the utility of cytology specimens for the interpretation of PD-L1 expression for the clinical management of NSCLC patients and shows that cytology smears can be used as a surrogate for evaluating PD-L1 expression in the absence of an FFPE specimen.
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